Even if a not negligible rate of patients with PTEN mutations do not meet diagnostic criteria for CS/PHTS, PTEN is known to be a tumor suppressor gene and the patients that show its mutation should be monitored because of the increased risk of developing malignancies [13,28]. This evidence concerns the gene PTEN and PTEN hamartoma tumor syndrome.